论文部分内容阅读
1 美国 FDA批准 Gleevec用于儿童美国 FDA已批准诺华公司的靶向抗癌药物 Gleevec(通用名 :imatinib mesylate)用于儿科。该药适用于患有费城染色体阳性的处于慢性期的慢性髓性白血病 (CML)儿童患者。这些患者都是经干细胞移植后疾病复发 ,或对 α干扰素治疗产生了耐受的患者。
1 FDA approves Gleevec for use in children U.S. FDA has approved Novartis’s targeted anti-cancer drug Gleevec (generic name: imatinib mesylate) for pediatric use. This medicine is suitable for children with chronic myelogenous leukemia (CML) who have a Philadelphia chromosome-positive chronic phase. These patients are those who have relapsed after a stem cell transplant or are refractory to alpha interferon therapy.